Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BYSI
BeyondSpring Inc.
stock NASDAQ

At Close
Jul 31, 2026 3:31:45 PM EDT
1.16USD+2.655%(+0.03)8,668
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 31, 2026 8:01:30 AM EDT
1.12USD-0.885%(-0.01)549
After-hours
Jul 31, 2026 4:00:30 PM EDT
1.15USD-0.862%(-0.01)925
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
05:34AM EST  BeyondSpring Pharmaceuticals Granted U.S. Patent #11,229,642 'Composition and method for reducing neutropenia'   Benzinga
Jan 12, 2022
08:30AM EST  The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award   Benzinga
05:44AM EST  BeyondSpring Cuts On-Third Of Its Workforce   Benzinga
Jan 11, 2022
04:06PM EST  BeyondSpring Reports Organizational Streamlining: Will Cut US Workforce By 35%   Benzinga
04:05PM EST  -- Resources to be Focused on Highest Value Business Activities -- 35% Reduction in Workforce in the U.S.Implemented to Preserve Long-Term Sustainability   GlobeNewswire Inc
Dec 30, 2021
08:39AM EST  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Dec. 30, 2021: BIIB, DIDI, FTFT, BYSI, PIXY   Benzinga
08:04AM EST  BeyondSpring Q3 EPS $(0.47) Up From $(0.48) YoY   Benzinga
08:00AM EST  - Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone   GlobeNewswire Inc
Dec 15, 2021
07:00AM EST  BeyondSpring Pharmaceuticals Announces New Clinical Data   GlobeNewswire Inc
Dec 10, 2021
08:12AM EST  BeyondSpring Pharmaceuticals To Present Two Posters At 2021 San Antonio Breast Cancer Symposium   Benzinga
08:00AM EST  -- The two posters will be presented on Friday, December 10, 2021 8:00 AM to 9:30 AM EST   GlobeNewswire Inc
Dec 6, 2021
07:56PM EST  Pomerantz LLP is investigating claims on behalf of investors of BeyondSpring Inc. (BeyondSpring or the Company) (NASDAQ: BYSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 2, 2021
11:22AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021   Benzinga
10:25AM EST  Mid-Morning Market Update: Markets Mostly Higher; Dollar General Posts Upbeat Q3 Earnings   Benzinga
07:30AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
05:18AM EST  Jefferies Downgrades BeyondSpring to Hold, Lowers Price Target to $5   Benzinga
04:51AM EST  B of A Securities Downgrades BeyondSpring to Underperform, Lowers Price Target to $5   Benzinga
Dec 1, 2021
03:35PM EST  Why BeyondSpring Shares Are Diving Today   Benzinga
02:34PM EST  Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet   Benzinga
12:45PM EST  Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide   Benzinga
10:08AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021   Benzinga
10:07AM EST  Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views   Benzinga
09:41AM EST  HC Wainwright & Co. Downgrades BeyondSpring to Neutral   Benzinga
09:17AM EST  Benzinga Pro's Top 4 Stocks To Watch For Wednesday, Dec. 1, 2021: RIOT, BYSI, AUVI, TTOO   Benzinga
08:10AM EST  BeyondSpring Shares To Resume Trade At 8:30 a.m. EST   Benzinga
08:04AM EST  BeyondSpring Pharmaceuticals Receives Complete Response Letter From FDA For Plinabulin New Drug Application   Benzinga
08:00AM EST  BeyondSpring Pharmaceuticals Receives Complete Response Letter   GlobeNewswire Inc
Nov 30, 2021
04:47PM EST  The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout   Benzinga
Nov 28, 2021
09:43AM EST  The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week   Benzinga
Nov 26, 2021
07:08AM EST  The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).   RTTNews
Nov 24, 2021
08:10AM EST  BeyondSpring Pharmaceuticals To Present At 4th Annual Evercore ISI HealthCONx Conference On Nov. 30 At 4:20 p.m. EST   Benzinga
08:00AM EST  BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore   GlobeNewswire Inc
Nov 12, 2021
08:00AM EST  BeyondSpring (the Company or BeyondSpring) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.   GlobeNewswire Inc
Nov 10, 2021
07:00AM EST  BeyondSpring Appoints Commercial Leader Mark Santos to its Board   GlobeNewswire Inc
Oct 21, 2021
12:11PM EDT  BeyondSpring Announces First Patient Treated In Phase 2 Study With Plinabulin Combined With Nivolumab + Ipilimumab In Patients In 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors   Benzinga
07:00AM EDT  The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S.   GlobeNewswire Inc
Oct 20, 2021
07:11AM EDT  BeyondSpring Announces New Patient-Derived Cancer Model Data For Plinabulin Monotherpy At The AACR-NCI-EORTC Virtual International Conference   Benzinga
07:00AM EDT  BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer   GlobeNewswire Inc
Sep 20, 2021
02:33PM EDT  Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge   Benzinga
12:31PM EDT  HC Wainwright & Co. Maintains Buy on BeyondSpring, Lowers Price Target to $65   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher   Benzinga
10:51AM EDT  BeyondSpring Down Despite Positive Results For Plinabulin   RTTNews
10:46AM EDT  Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B   Benzinga
09:26AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Sept. 20, 2021: PFE, ZIVO, VC, ASAX, BYSI   Benzinga
07:33AM EDT  BeyondSpring Pharmaceuticals Announces Final Phase 3 DUBLIN-3 Data With Plinabulin/Docetaxel Combination Versus Docetaxel Alone At ESMO 2021 Event   Benzinga
07:30AM EDT  BeyondSpring Pharmaceuticals Announces Positive Final Phase 3   GlobeNewswire Inc
Sep 16, 2021
11:50AM EDT  BeyondSpring Presents New Plinabulin Data At ESMO Congress   Benzinga
07:02AM EDT  BeyondSpring Pharmaceuticals Announces Poster Presentation Of Data Of Plinabulin At European Society for Medical Oncology 2021 Congress   Benzinga
07:00AM EDT  BeyondSpring Pharmaceuticals Announces New Positive Data on   GlobeNewswire Inc
Sep 15, 2021
09:51AM EDT  Earnings Scheduled For September 10, 2021   Benzinga
Sep 14, 2021
07:22AM EDT  BeyondSpring: Q2 Earnings Insights   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
07:30AM EDT  BeyondSpring Q2 Loss Per Share $0.46 Vs Loss $0.49 Last Year   RTTNews
07:01AM EDT  BeyondSpring Q2 EPS $(0.49) Misses $(0.48) Estimate   Benzinga
07:00AM EDT  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate events.   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For September 10, 2021   Benzinga
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
07:22AM EDT  BeyondSpring Announces Three Poster Presentations About Its Chemotherapy-Induced Neutropenia Prevention Program At The European Society For Medical Oncology 2021 Congress   Benzinga
07:00AM EDT  -- Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021.   GlobeNewswire Inc
06:54AM EDT  BeyondSpring Pharmaceuticals Filed U.S. Patent Application #20210275524 'METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION'   Benzinga
06:54AM EDT  9-Sep-21 20210275524 BeyondSpring Pharmaceuticals Filed U.S. Patent Application #20210275524 'METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION'   Benzinga
05:20AM EDT  Baird Initiates Coverage On BeyondSpring with Outperform Rating, Announces Price Target of $50   Benzinga
Sep 8, 2021
05:54PM EDT  BeyondSpring Inc. (BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will present at and participate in the Morgan Stanley 19th Annual Global Healthcare Conference and R.W. Bairds 2021 Global Healthcare Conference. Details for both conferences are below:   GlobeNewswire Inc
04:19PM EDT  BeyondSpring Shares Spike On Volume, Hearing Baird Initiates With Outperform, $50 Price Target   Benzinga
Sep 7, 2021
08:00AM EDT  BeyondSpring to Host Second Quarter Financial Results and   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
07:01AM EDT  BeyondSpring To Present Final Phase 3 DUBLIN-3 Data With Plinabulin/Docetaxel Combination Versus Docetaxel Alone In 2nd/3rd Line Non-Small Cell Lung Cancer Patients With EGFR Wild Type At European Society for Medical Oncology 2021 Congress Sept. 16-21   Benzinga
07:00AM EDT  -- Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and incidence of Grade 4 neutropenia.   GlobeNewswire Inc
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
07:10AM EDT  BeyondSpring Announced Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China   Benzinga
07:00AM EDT  -- Wanchunbulin, BeyondSprings 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and co-development rights for plinabulin in Greater China markets (the Territory)   GlobeNewswire Inc
Aug 19, 2021
03:23PM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021   Benzinga
Aug 10, 2021
08:00AM EDT  -- Distinguished industry executive and entrepreneur recognized for the development of a first-in-class asset in the oncology space   GlobeNewswire Inc
Aug 9, 2021
01:01PM EDT  BeyondSpring Option Alert: Jan 21 $40 Calls Sweep (12) near the Ask: 113 @ $8.0 vs 78 OI; Earnings 9/2 Before Open [est] Ref=$26.58   Benzinga
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 6, 2021
10:18AM EDT  Mid-Morning Market Update: Markets Mostly Higher; US Economy Adds 943,000 Jobs   Benzinga
Aug 5, 2021
11:41AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang Says Next To The Plinabulin Trials The Co Also Has 3 Other Pre-Clinical Drug Trials In The Pipeline   Benzinga
11:38AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang Says Co Has $91 Million On The Balance Sheet, Says This Will Take The Co Until 2022 July.   Benzinga
11:37AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang Says Co Does Not Have Any Plans Now To Raise Extra Money And Do An Offering   Benzinga
11:36AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang Says Co Is Planning To Discuss The Co's Positive DUBLIN-3 Trial Of Plinabulin With The FDA Later This Year   Benzinga
11:32AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang Now Interviewing On Benzinga Tv   Benzinga
10:16AM EDT  EXCLUSIVE: BeyondSpring CEO And Co-Founder, Dr. Lan Huang To Appear On Benzinga Tv At 11:30 a.m. EDT   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
02:30PM EDT  Mid-Afternoon Market Update: Dow Falls 275 Points; BeyondSpring Shares Spike Higher   Benzinga
10:34AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021   Benzinga
10:19AM EDT  Mid-Morning Market Update: Markets Mostly Lower; General Motors Tops Q2 Views   Benzinga
10:19AM EDT  BeyondSpring Shares Move Higher; Hearing Evercore Raises Price Target From $30 To $95   Benzinga
09:55AM EDT  Shares of BeyondSpring Inc. (BYSI) surged over 150% on Wednesday morning after the company reported positive results from a lung cancer treatment trial.   RTTNews
09:09AM EDT  HC Wainwright & Co. Upgrades BeyondSpring to Buy, Announces $100 Price Target   Benzinga
09:02AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Aug. 4, 2021: BYSI, FSLY, BBIG, WEBR, ETON   Benzinga
07:03AM EDT  BeyondSpring Announces DUBLIN-3 Registrational Trial Met Primary Endpoint And Key Secondary Endpoints; Plans To Seek US FDA And China NMPA Approval For Plinabulin In Combination With Docetaxel   Benzinga
07:00AM EDT  BeyondSpring Announces Positive Topline Results from its DUBLIN-3   GlobeNewswire Inc
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 8, 2021
08:02AM EDT  BeyondSpring to Participate in the William Blair Biotech Focus   GlobeNewswire Inc
Jul 2, 2021
04:10PM EDT  BeyondSpring Files Prospectus Related To Offer, Sale, From Time To Time Of Up To 10M Ordinary Shares   Benzinga
Jun 29, 2021
10:12AM EDT  BeyondSpring Pharmaceuticals Granted U.S. Patent Titled 'Method of treating cancer associated with a RAS mutation'   Benzinga
Jun 17, 2021
04:00PM EDT  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the development program for its novel immune agent, Plinabulin, in anti-cancer indications on Friday, June 25th, at 8:00 a.m. ET.   GlobeNewswire Inc
Jun 16, 2021
08:05AM EDT  BeyondSpring Q1 EPS $(0.58) Misses $(0.54) Estimate   Benzinga
08:00AM EDT  - NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For June 16, 2021   Benzinga
Jun 11, 2021
08:00AM EDT  BeyondSpring Inc. (BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.   GlobeNewswire Inc
Jun 10, 2021
07:04AM EDT  BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology Annual Meeting   Benzinga
07:00AM EDT  - Data further supports plinabulins fast onset of action and CIN prevention benefit in week 1 following chemotherapy   GlobeNewswire Inc
Jun 8, 2021
07:17AM EDT  BeyondSpring To Present PROTECTIVE-2 Phase 3 Data On Plinabulin In Combination With Pegfilgrastim At Federation of Clinical Immunology Societies Annual Meeting Jun. 8-11   Benzinga
07:00AM EDT  BeyondSpring Announces a Late-Breaking Poster Presentation of   GlobeNewswire Inc
Jun 7, 2021
07:04AM EDT  BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of ASCO   Benzinga
07:00AM EDT  - Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone   GlobeNewswire Inc
Jun 4, 2021
07:17AM EDT  BeyondSpring Doses First Patient In A Triple Combination Study With Plinabulin   RTTNews
07:04AM EDT  BeyondSpring Reports First Patient Dosed In Triple-Combo Study With Plinabulin, PD-1/PD-L1 Inhibitor, Radiotherapy For Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors   Benzinga
07:00AM EDT  -- Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy -- First patient who failed Keytruda and chemotherapy has been dosed with plinabulin, Keytruda and radiation combination in non-small cell lung cancer (NSCLC)   GlobeNewswire Inc
Jun 1, 2021
11:45AM EDT  BeyondSpring's Plinabulin US Application for Chemo-Induced Neutropenia Under Review   Benzinga
08:19AM EDT  BeyondSpring Inc. (BYSI) said that the U.S. Food and Drug Administration has accepted for filing, and with Priority Review, the company's New Drug Application or NDA seeking approval for use of plinabulin in combination with granulocyte colony-stimulating factor or G-CSF for the prevention of chemotherapy-induced neutropenia or CIN.   RTTNews
07:12AM EDT  BeyondSpring: FDA Accepts For Filing, With Priority Review, NDA For Plinabulin And G-CSF Combination   RTTNews
07:05AM EDT  BeyondSpring Announces FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-CSF Combination For Prevention Of Chemotherapy-Induced Neutropenia   Benzinga
07:00AM EDT  - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021   GlobeNewswire Inc
May 26, 2021
04:05PM EDT  BeyondSpring Inc. (BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 am ET and will be available for 1x1 meetings.   GlobeNewswire Inc
May 24, 2021
07:38AM EDT  BeyondSpring Announces Poster Presentation Of An Investigator-initiated Phase 1 Study   RTTNews
07:31AM EDT  BeyondSpring Highlights Presentation Of Phase 1 Data On Plinabulin In Combination With Checkpoint Inhibitors At American Society Of Clinical Oncology Annual Meeting   Benzinga
07:30AM EDT  - Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability.   GlobeNewswire Inc
May 10, 2021
08:18AM EDT  BeyondSpring Inc. (BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 8:00 am ET and will be available for 1x1 meetings.   GlobeNewswire Inc
Apr 30, 2021
08:00AM EDT  BeyondSpring Files 2020 Annual Report on Form 20-F   GlobeNewswire Inc
07:03AM EDT  BeyondSpring Reports Q4 Net Loss of $17.6M, Compared To $14.1M YoY   Benzinga
07:00AM EDT  - NDAs filed in the U.S. and China in Mar. 2021based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN   GlobeNewswire Inc
04:12AM EDT  Earnings Scheduled For April 30, 2021   Benzinga
Apr 27, 2021
11:23AM EDT  BeyondSpring to Announce Fourth Quarter and Year End 2020   GlobeNewswire Inc
Apr 5, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2021   Benzinga
06:11AM EDT  A Peek Into The Markets: US Stock Futures Gain After Upbeat Jobs Data   Benzinga
06:09AM EDT  HC Wainwright & Co. Downgrades BeyondSpring to Neutral   Benzinga
Apr 1, 2021
07:11AM EDT  BeyondSpring Files US-China Application For Plinabulin G-CSF Treatment In Chemo-Induced Neutropenia   Benzinga
12:20AM EDT  BeyondSpring Submits NDA To FDA And China NMPA For Plinabulin And G-CSF Combination For Chemotherapy-Induced Neutropenia   RTTNews
Mar 31, 2021
11:21PM EDT  Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone   GlobeNewswire Inc
Mar 11, 2021
04:01PM EST  BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for   GlobeNewswire Inc
Jan 11, 2021
10:06AM EST  Benzinga's Top Upgrades, Downgrades For January 11, 2021   Benzinga
07:31AM EST  B of A Securities Initiates Coverage On BeyondSpring with Buy Rating, Announces Price Target of $25   Benzinga
Dec 29, 2020
10:12AM EST  Benzinga's Top Upgrades, Downgrades For December 29, 2020   Benzinga
09:19AM EST  UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare   GlobeNewswire Inc
08:00AM EST  BeyondSpring to Present at the J.P. Morgan Healthcare Conference   GlobeNewswire Inc
06:39AM EST  Evercore ISI Group Initiates Coverage On BeyondSpring with Outperform Rating, Announces Price Target of $30   Benzinga
Dec 17, 2020
08:13AM EST  BeyondSpring Appoints Jeffrey Vacirca To Its Board   RTTNews
08:00AM EST  BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to   GlobeNewswire Inc
Dec 10, 2020
08:06AM EST  BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results At The 2020 San Antonio Breast Cancer Symposium   Benzinga
08:00AM EST  - The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 24, 2020
08:59PM EST  -- BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium   GlobeNewswire Inc
Nov 23, 2020
04:01PM EST  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.   GlobeNewswire Inc
Nov 19, 2020
03:12PM EST  BeyondSpring Earlier Priced 7.5M Share Common Stock Offering At $10/Share   Benzinga
08:00AM EST  BeyondSpring Announces Pricing of Ordinary Shares   GlobeNewswire Inc
Nov 18, 2020
02:31PM EST  Mid-Afternoon Market Update: Dow Falls Over 100 Points; BeyondSpring Shares Plunge   Benzinga
12:09PM EST  Mid-Day Market Update: PaySign Falls After Q3 Earnings; VAALCO Energy Shares Jump   Benzinga
Nov 17, 2020
04:02PM EST  BeyondSpring Announces A Common Stock Offering Of $75 Million   Benzinga
04:01PM EST  BeyondSpring Announces Proposed Public Offering of Ordinary Shares   GlobeNewswire Inc
08:15AM EST  BeyondSpring Q3 EPS $(0.48) Down From $(0.37) YoY   Benzinga
08:00AM EST  - Announced SEED Therapeutics Inc.(SEED)s collaboration with Eli Lilly and Company(Lilly)   GlobeNewswire Inc
Nov 16, 2020
07:10AM EST  BeyondSpring Phase 3 PROTECTIVE-2 Study Met it Primary Endpoint   Benzinga
07:00AM EST  BeyondSpring Announces Positive Topline Results from its   GlobeNewswire Inc
Nov 13, 2020
04:46PM EST  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the Jefferies London Healthcare Conference on November 17th. Details are as follows:   GlobeNewswire Inc
07:25AM EST  BeyondSpring: Seed Therapeutics Enters Research Collaboration, License Agreement With Eli Lilly   RTTNews
07:09AM EST  BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration And License Agreement With Lilly; Seed To Receive $10M Upfront Cash Payment, $10M Equity Investment From Lilly And Up To ~$780M In Milestones   Benzinga
07:00AM EST  - Seed Therapeutics to Use Proprietary Molecular Glue Protein Degradation Technology to Develop Potential New Medicines -   GlobeNewswire Inc
Nov 3, 2020
08:30AM EST  BeyondSrping Files For Shelf Of Up To 10M Shares   Benzinga
Oct 14, 2020
07:02AM EDT  BeyondSpring Subsidiary Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer   Benzinga
07:00AM EDT  Seed Therapeutics Inc. (the Company or Seed Therapeutics), a global research company and BeyondSpring subsidiary focused on harnessing and engineering molecular glue, a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced the Companys appointment of Edward Dongheng Liu as Chief Financial Officer.   GlobeNewswire Inc
Oct 12, 2020
07:00AM EDT  BeyondSpring Forms Partnership Advisory Committee Comprised of   GlobeNewswire Inc
Sep 29, 2020
08:00AM EDT  JAMA OncologyHighlights Plinabulin's Efficacy in   GlobeNewswire Inc
Sep 24, 2020
08:05AM EDT  BeyondSpring Highlights Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19   Benzinga
08:00AM EDT  New Data Highlights BeyondSprings Plinabulin as   GlobeNewswire Inc
Sep 22, 2020
08:43AM EDT  BeyondSpring Appoints Elizabeth Czerepak As CFO   RTTNews
08:35AM EDT  BeyondSpring Appoints Elizabeth Czerepak As Chief Financial Officer   Benzinga
Sep 11, 2020
08:00AM EDT  BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global   GlobeNewswire Inc
Sep 8, 2020
07:19AM EDT  BeyondSpring Receives Breakthrough Therapy Designations From Both U.S. FDA And China NMPA For Plinabulin   RTTNews
07:03AM EDT  BeyondSpring Receives Breakthrough Therapy Designations From Both US FDA And China NMPA For Plinabulin In Chemotherapy-Induced Neutropenia Indication   Benzinga
07:00AM EDT  - FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention of Chemotherapy-Induced Neutropenia (CIN) -   GlobeNewswire Inc
Sep 3, 2020
07:14AM EDT  BeyondSpring Q2 EPS $(0.46) Beats $(0.57) Estimate   Benzinga
07:00AM EDT  - Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulins Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone-   GlobeNewswire Inc
04:16AM EDT  Earnings Scheduled For September 3, 2020   Benzinga
Aug 27, 2020
08:00AM EDT  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3rd, 2020, at 8 a.m. Eastern Time.   GlobeNewswire Inc
Aug 18, 2020
08:00AM EDT  BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford   GlobeNewswire Inc
Aug 11, 2020
08:20AM EDT  BeyondSpring Initiates Expanded Access Program With Plinabulin For Patients Suffering From CIN In The U.S.   Benzinga
08:00AM EDT  - NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -   GlobeNewswire Inc
Jul 27, 2020
05:22PM EDT  BeyondSpring 13D Shows Decheng Capital China Life Sciences USD Fund II Holds 5.7% Active Stake In Co.   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC